We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Meridian Bioscience Launches Novel Ready-to-Use, Air-Dryable RT-qPCR Mix for COVID-19 Assay Development

By HospiMedica International staff writers
Posted on 04 Dec 2020
A newly-launched novel air-dryable RT-qPCR mix aims to further decrease costs and simplify workflows for manufacturers of COVID-19 molecular tests.

Meridian Bioscience, Inc. (Cincinnati, OH, USA) has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. The specialized master mix is designed for air-drying, a cost-effective and easier alternative to lyophilization.

Illustration
Illustration

While molecular diagnostic tests are progressively moving towards a dried-down format, there are technical challenges in developing lyophilization-compatible mixes that require lengthy optimization and expensive lyophilization equipment. Meridian has developed a ready-to-use, air-dryable RT-qPCR mix to meet the growing demand within the molecular diagnostics industry for an easier and more cost-effective method of drying RNA assays.

Meridian’s Air-Dryable RT-qPCR Mix has been designed to simplify development, manufacturing and storage of molecular assays while delivering fast detection of RNA targets, an ideal solution for COVID-19 assay development. Its one-tube format chemistry containing all reagents necessary for a RT-qPCR, including magnesium, dNTP and reverse transcriptase, not only shortens assay optimization but is also compatible with air-drying protocols. The new mix shows exceptionally high performance in both singleplex and multiplex reactions following rehydration, making it ideally suited for a wide range of instruments from automated high-throughput platforms to point-of-care devices.

“Over the last 12 months, we have seen a significant increase in demand for our Lyo-Ready RT-qPCR mixes; however, not all our customers have the expertise in-house to lyophilize,” said Florent Chang-Pi-Hin, PhD, Senior Director of Research and Development at Meridian Bioscience. “Building on the launch of our Air-Dryable qPCR Mix earlier this year, our new Air-Dryable RT-qPCR Mix represents a perfect solution for the development of ambient temperature stable assays for RNA targets, which is so important today with the global fight against SARS-CoV-2.”

Related Links:
Meridian Bioscience, Inc.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Mini C-arm Imaging System
Fluoroscan InSight FD
New
Monitor Cart
Tryten S5

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles